Effects of indoramin and metoprolol on plasma lipids and lipoproteins.
The effects of indoramin (n = 29) and metoprolol (n = 15) on lipid profiles in hypertensive patients were compared in a double-blind study. Blood samples were taken at baseline, weeks 3 and 4 of placebo administration, and after 4 and 8 weeks of active treatment. The following assays were performed: total cholesterol, total triglycerides, high density lipoprotein (HDL) cholesterol, HDL3 cholesterol, and apoproteins A, AI, and B. The following values were calculated: HDL2 cholesterol, low density lipoprotein (LDL) cholesterol, total cholesterol/HDL cholesterol ratio (Castelli risk ratio I), and LDL cholesterol/HDL cholesterol (Castelli risk ratio II). The results of an overall analysis showed the following significant changes (mean +/- SD) for indoramin: LDL cholesterol, from 129.50 +/- 38.29 to 114.00 +/- 32.41 mg/dl (p less than or equal to 0.001); apoprotein A, from 169.51 +/- 39.83 to 232.48 +/- 34.08 mg/dl (p less than or equal to 0.001); apoprotein AI, from 105.62 +/- 20.70 to 134.68 +/- 21.58 mg/dl; apoprotein B, from 110.13 +/- 34.88 to 122.34 +/- 32.13 mg/dl (p less than or equal to 0.05); and Castelli risk ratio II, from 2.38 to 1.96 (p less than or equal to 0.01). The following significant variations occurred for metoprolol: total cholesterol, from 201.54 +/- 49.21 to 191.80 +/- 51.88 mg/dl (p less than or equal to 0.05); apoprotein A, from 186.78 +/- 62.63 to 227.68 +/- 44.78 mg/dl (p less than or equal to 0.001); apoprotein AI, from 109.12 +/- 34.72 to 131.95 +/- 21.79 mg/dl (p less than or equal to 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)
Martinez
T L
TL
Auriemo
C R
CR
Machado
A M
AM
Cunha
M A
MA
Feres
M C
MC
Maldjian
S
S
Wortsman
A
A
Delboni
F O
FO
D000293:Adolescent; D000328:Adult; D000368:Aged; D016632:Apolipoprotein A-I; D001054:Apolipoproteins A / Q000097:blood; D001055:Apolipoproteins B / Q000097:blood; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000188:drug therapy; D007211:Indoles / Q000627:therapeutic use*; D007217:Indoramin / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood*; D008075:Lipoproteins, HDL / Q000097:blood; D008297:Male; D008790:Metoprolol / Q000627:therapeutic use*; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood
D016632:Apolipoprotein A-I; D001054:Apolipoproteins A; D001055:Apolipoproteins B; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D007211:Indoles; D008055:Lipids; D008074:Lipoproteins; D008075:Lipoproteins, HDL; D014280:Triglycerides; D007217:Indoramin; D002784:Cholesterol; D008790:Metoprolol